Naesens, L.

adefovir patient response treatment lam adv hepatitis treatment failure hepatitis b failure therapy adefovir treatment study level suboptimal resistance virus serum adefovir dipivoxil virological response suboptimal response 10 patients blood concentration hepatitis b virus study log 10 adv treatment adefovir plasma concentration infection iu /ml adv range fl uorescence detection hepatology plasma gastroenterology department tenofovir dipivoxil hannover variant adefovir therapy drug administration inhibitor adefovir resistance drug resistance tenofovir treatment virological publishing 6 months table hbv-dna time point blackwell drug levels protease inhibitors range 2–8 h lam tenofovir etv responder polymerase discussion patient characteristics european administration plasma adefovir concentration hepg 2 cells hepatitis c virus sample adefovir serum levels hiv fi eld health õ programme zoulim adv-treated hepatitis b lam tenofovir adv treatment response groups ficient blood drug levels protease adv etv adv deterding entecavir adefovir dipivoxil therapy erasmus mc university